Time to bet on Lundbeck’s pipeline execution potential
30/05/25 -"After some of the key patent expiries at the start of this decade, Lundbeck has been growing at a healthy pace, on the back of its four main products. Moreover, the firm has proactively utilized its ..."
Pages
57
Language
English
Published on
30/05/25
You may also be interested by these reports :
02/06/25
We have updated our estimates with the latest figures. The EPS has improved due to lower-than-expected R&D costs. This improvement is supported by ...
01/06/25
CureVac has repositioned itself as an early-stage biotech company following the out-licensing of its infectious disease portfolio to GSK. The deal ...
30/05/25
Faes Farma (+25% ytd) has been one of the best performing European pharmas in our coverage this year, driven by the strength of its operations and ...
30/05/25
After some of the key patent expiries at the start of this decade, Lundbeck has been growing at a healthy pace, on the back of its four main ...